Mucosal Remodeling in Chronic Rhinosinusitis with Nasal Polyps: The Role of Innate Lymphoid Cells and Reprogramming...

Area of Science:

• Immunology
• Respiratory Medicine
• Cell Biology

Background:

• The nasal mucosa is a complex barrier involving epithelial, stromal, neuronal, and immune cells.
• Type 2 innate lymphoid cells (ILC2s) are key players in type 2 inflammation, releasing IL-5 and IL-13, which contribute to conditions like chronic rhinosinusitis with nasal polyps (CRSwNP) and allergic rhinitis.
• Recent research highlights ILC plasticity, progenitor cells, and the impact of metabolic and neuroimmune factors on ILC function.

Purpose of the Study:

• To review the current understanding of ILCs in the nasal mucosa, focusing on their role in type 2 inflammation.
• To explore the immunomodulatory effects of dupilumab, an IL-4Rα inhibitor, on the epithelial-ILC axis.
• To discuss the potential of ILC profiling as a biomarker for treatment response in CRSwNP and allergic rhinitis.

Main Methods:

• Literature review synthesizing current knowledge on ILCs, epithelial-ILC communication, and dupilumab's mechanism of action.
• Analysis of clinical and translational studies investigating ILC phenotypes and treatment responsiveness.
• Integration of data on ILC plasticity, progenitor biology, and metabolic/neuroimmune influences.

Main Results:

• ILC2s are central to type 2 inflammation in the nasal mucosa, exacerbating conditions like CRSwNP through IL-5 and IL-13 production.
• Dupilumab effectively dampens ILC2 effector functions by blocking IL-4/IL-13 signaling, restoring epithelial integrity and rebalancing immune responses.
• Baseline ILC2 phenotypes, especially inflammatory subsets, may predict patient response to dupilumab therapy.

Conclusions:

• Innate lymphoid cells are critical drivers of nasal type 2 inflammation and represent promising targets for precision immunomodulation.
• Dupilumab offers a targeted therapy by modulating the epithelial-ILC axis, providing a framework for personalized treatment in CRSwNP and allergic rhinitis.
• ILC profiling holds potential as a biomarker strategy for guiding personalized treatment decisions.